MiMedx Group (NASDAQ:MDXG) Reaches New 1-Year Low – Should You Sell?

MiMedx Group, Inc (NASDAQ:MDXG)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $5.05 and last traded at $5.09, with a volume of 1174179 shares changing hands. The stock had previously closed at $5.11.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho decreased their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Finally, Lake Street Capital lowered their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Trading Down 0.4%

The company has a market capitalization of $753.84 million, a PE ratio of 18.85 and a beta of 1.57. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The company’s fifty day moving average is $6.39 and its 200-day moving average is $6.81.

Insider Activity

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the transaction, the insider directly owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. The trade was a 19.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On MiMedx Group

A number of large investors have recently added to or reduced their stakes in MDXG. CWM LLC boosted its holdings in shares of MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after buying an additional 1,892 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after acquiring an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in MiMedx Group in the third quarter worth $54,000. Headlands Technologies LLC acquired a new position in shares of MiMedx Group during the second quarter worth $72,000. Finally, Osaic Holdings Inc. lifted its holdings in shares of MiMedx Group by 57.2% during the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock valued at $79,000 after purchasing an additional 4,708 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.